Abstract
Introduction
The BCR-ABL negative myeloproliferative neoplasms (MPN), Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) are malignant diseases arising from a mutant multipotent hematopoietic stem cell (HSC) 1, 2 , that are associated with constitutively active JAK-STAT signaling. The JAK2 V617F mutation is present in 95% of PV, 50% of ET and PMF 3, 4, 5, 6 . JAK2 exon 12 mutations are found in a minority of PV patients 7 . 5% of PMF and 1% of ET harbor thrombopoietin receptor (MPL, TpoR) W515 mutations 8, 9 , which constitutively activate JAK2 signaling 10 .
Moliterno et al. have reported diminished platelet MPL expression in MPNs 11 and an inverse correlation between JAK2 V617F allele burden and MPL expression, although downmodulation of MPL was observed also in JAK2 V617F-negative patients 12 . This suggests that mechanisms that limit the expression, surface localization and function of MPL might operate during the establishment of MPNs.
We searched for putative microRNAs 13 that target the 3'UTR of the MPL mRNA. We found that miR-28 is an inhibitor of MPL translation, which is also the case for two close relatives of miR-28, miR-151 and miR-708. We identified several miR-28 targets, besides MPL, such as E2F6, a transcription factor involved in the control of proliferation and apoptosis, and the MAP-kinase MAPK1/ERK2. We then detected induction of miR-28 in cell lines transformed by JAK2 V617F or activated MPL mutants. We have also investigated levels of expression of miR-28 in platelets from healthy subjects and MPN patients.
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Materials and methods

Cell lines, plasmid/luciferase constructs and reagents
Human erythroleukemia (HEL), JAK2-deficient cell γ2A, UT-7, Mo-7e and Ba/F3 cells were maintained as described 14, 15, 16, 17, 18 . The UKE-1 cell line was a kind gift of Dr. Walter
Fiedler, University Hospital Eppendorf, Hamburg, Germany. Translational inhibition by microRNAs was measured using the psi-CHECK™-2 reporter vector (Promega). Briefly, 3'UTR specific primers extended with adaptor sequences corresponding either to a NotI or XhoI site were used in a PCR reaction. PCR products were cloned in the TOPO vector (Invitrogen) and positive clones were digested by NotI and XhoI and ligated in the digested psi-CHECK™-2 vector. After sequencing, the microRNA target sites were mutated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) following manufacturer instructions.
These plasmid constructs (0.8 µg) were transfected with 40 nM pre-miR™ (Ambion) in γ2A cells using Lipofectamine (Invitrogen). Luciferase activities were assayed 48 h after transfection using the Dual-Luciferase® Reporter Assay System (Promega).
Pri-miRs were amplified with pri-miR-28 primers (28s GGCAACATCTAAATATGGCTTG; 28a TGAGGTAGGCAGTATTAGCTCTGA), pri-miR-708 primers (708s GAAACCTAACCCCCATGGTT; 708a TAGAGGGTCCTCAGGTGGTG) and pri-miR-151 primers (151s AGCTGAGCCTGGTGCTAGTC; 151a ATTCAGTGCCTGGGTGACTC), cloned in Topo TA vector (Invitrogen), digested by EcoRI and ligated in pMEGIX-IRES-GFP. All constructs were verified by sequencing. Retroviral transduction were performed as described 19 . The dominant negative STAT5 (STAT5A∆749) (originally described by Dr. T.
Kitamura) was cloned in pREX-IRES-CD2 and used for Ba/F3 TpoR JAK2 V617F or HEL cells electroporations. JAK2 inhibitors were from Calbiochem (JAK inhibitor 1), Astra Zeneca (AZD1480), Sigma (AG490) and SYN|thesis med chem (TG101209).
Patient samples
Platelets were isolated from MPN patients of Hôpital Henri Mondor, Paris and from St Luc Hospital, Brussels. Blood samples were obtained with approval of all participating institutions' Ethical Committees and informed consent in accordance with the Declaration of Helsinki. The JAK2 V617F and MPL W515 status was determined by TaqMan PCR and sequencing as described 12 .
Real-Time quantitative PCR
Total RNA, including miRNA and other small RNA molecules, was isolated using TRIzol Expression analysis of the LPP gene was performed by real-time PCR with the following primers: LPPs GTGCAATGTGTGTTCCAAGC; LPPa TGGCATAATAGGCTCCTTGC.
Data were normalized to beta-actin amplified with the following primers: ACTBs CCTGGCACCCAGCACAAT; ACTBa GGGCCGGACTCGTCATACT.
5'-Rapid Amplification of cDNA Ends (5'RACE-PCR)
Amplification of 5' ends of LPP mRNAs was performed using the SMART RACE cDNA Amplification Kit protocol (Clontech) and LPP gene specific primers: LPP-GSP1
TGGCAGCCAAGATGGGTGAGACATT and LPP-GSP2
CCTCTGATGAGCGTCCAGTGGAACA. The PCR products were analyzed on a 1.2 % agarose gel. PCR bands were excised and purified with the QIAquick gel extraction kit (Qiagen). Purified DNAs were cloned with the TOPO TA cloning kit (Invitrogen) and eight positive clones from each transformation were sequenced.
Chromatin immunoprecipitation
Chromatin cross-linking, cell lysis and DNA shearing were performed as described 21 .
Immunoprecipitation was performed with the OneDay chromatin immunoprecipitation (ChIP) 
Retroviral transductions
Retroviruses produced after BOSC packaging cells transfections were used to infect Ba/F3 cells as described 19 . GFP positive cells were sorted 72 hours after infection. Cell numbers were recorded with a Coulter cell counter.
CD34 cultures and megakaryocyte differentiation in liquid culture
Liquid cultures using human CD34+ cells were retrovirally transduced with bicistronic viruses coding for miR-28, empty vector (pMegix) and GFP. Cells were maintained in serumfree medium containing Tpo and proplatelet counting was performed on GFP/CD41 double positive megakaryocytes, as described
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. Megakaryocyte micrographs (x40 objective) were taken with a Nikon TE300 microscope (Tokyo, Japan) at 37 °C in serum-free medium containing Tpo. Photos were taken with an AxioCamMR camera and processed with AxioVisionRel.4.6, CarlZeiss (Göttingen, Germany)
Western blotting
MPL protein levels were evaluated in Mo7e cell using the Anti-TpoR/c-Mpl antibody (Millipore, 06-944). Cells were harvested, washed in cold PBS and resuspended in cold NP40
Lysis Buffer (50mM Tris-Cl pH8, 150 mM NaCl, 1% NP40, 0.1 mM EDTA, 10 mM NaF, 1 mM Na 3 VO 4 , 1 mM PMSF, 1 mM DTT). Upon incubation on ice for 30 min with occasional vortexing, lysates were centrifuged for 20 min at 20,000 g and 4°C. Supernatants were collected and protein quantification were performed with the BCA™ Protein Assay Kit (Pierce). Protein extracts (50 µg) were loaded on NuPage 4-12% Bis-Tris gels (Invitrogen) and Western blot analysis was performed using a 1:1,000 MPL antibody and 1:10,000 dilution anti-rabbit-horseradish peroxidase antibodies (GE Healthcare, UK). The membranes were stripped and reprobed with anti-actin beta (monoclonal anti-ACTB, Sigma-Aldrich).
Results
The MPL 3'UTR is a target of miR-28
Five potential microRNA targets were identified with the miranda (http://www.microrna.org) and miRBase (http://microrna.sanger.ac.uk) programs in the 3'UTR MPL mRNA, starting at nucleotides 2,157; 2,531; 2,711; 2,836 and 3,524. The MPL 3'UTR was cloned downstream the luciferase coding region of a reporter vector and used to test the ability of microRNAs to inhibit translation. None of the let-7 family (let-7a, c, d, e, f and miR-98) pre-miRs (precursor of microRNA) inhibited translation (Fig. 1A) . miR-28 inhibited the luciferase activity by ∼ 30%, as compared to the activity of a control microRNA, that does not recognize any potential target. Since miR-28 could potentially bind to two distinct sites (starting at nucleotides 2,157 and 3,524, respectively), we performed mutagenesis of each of these sites ( Supplementary Fig. 1 ). We observed that mutagenesis of nucleotides 3,530-3,542 relieved the inhibition of luciferase activity by miR-28, while mutagenesis of the region encompassing nucleotides 2,168-2,174 did not. Thus, miR-28 inhibited luciferase expression by binding to MPL 3'UTR nucleotides 3,524-3,545.
To assess whether miR-28 inhibits translation of endogenous MPL, we transduced the human Mo7e cell line with a bicistronic retroviral vector expressing miR-28 along with the GFP.
Mo7e cells express endogenous MPL and can proliferate in medium supplemented with MPL ligand thrombopoietin (Tpo). Cells infected with the empty retrovirus (pMegix) or miR-28 expressing retrovirus (miR-28) were sorted for equivalent GFP levels. We observed an inhibition of MPL translation by miR-28 (Fig. 1B) . Importantly, expression of miR-28 did not reduce the level of endogenous mRNA for MPL in Mo7e or in HEL cells (not shown).
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We identified two microRNAs related to miR-28 (paralogs) with the BLASTN program found on the miRBase web site (http://microrna.sanger.ac.uk/). miR-151 has 80% sequence identity with miR-28, and miR-708 is 68% identical to miR-28 and 71% with miR-151. Mo7e cells were infected with bicistronic retroviral vectors coding for miR-28, 708 or 151 along with the GFP. After sorting for equivalent GFP levels, we monitored MPL protein levels ( Fig. 2A) and Tpo induced cell proliferation (Fig. 2B) . miR-28 and miR-708 were both inhibiting MPL translation by about 20%, while miR-151 inhibited it by 50%. miR-151 was also more potent that miR-28 or -708 for inhibition of Tpo mediated cell proliferation . Thus, miR-28 and sequence related miRs inhibit Tpo induced proliferation by MPL down-regulation.
Furthermore, as expected from the functional data, all the miRs targeted the MPL 3'UTR for translational inhibition (Fig. 2C ). The combination of miR-28 with miR-151 and miR-708 did not result in significantly synergic inhibition of luciferase activity, consistent with the notion that they all target the same sequence in the 3'UTR of MPL (Fig. 2C ). retained for further analysis. We next selected mRNAs expressed in blood cell lineages (http://genome.ucsc.edu). Five targets were selected: N4BP1, OTUB1, TEX261, MAPK1 and E2F6. We tested using the psi-CHECK TM -2 luciferase reporter assay the ability of these microRNAs to inhibit translation of the five targets (Fig. 2D ). We observed an up to 80%
inhibition of N4BP1 (NEDD4 binding protein 1), a regulator of the E3 Ubiquitin Ligase- , by all three miRs. OTUB1 (Otubain1), an inhibitor of GRAIL (gene related to anergy in lymphocytes), and TEX261 (testis expressed 261) were both inhibited by miR-28 and -708 by about 40%. MAPK1 (mitogen-activated protein kinase 1 Transcript variant 1 also known as Extracellular regulated kinase 2-ERK2) was inhibited by miR-28 by 40%. E2F6 (E2F transcription factor 6) was inhibited by miR-28 and -151 by 40% and 20%, respectively. E2F6 is a negative regulator of E2F1 transcription factor involved in cell-cycle regulation and apoptosis 24 . MPL and the last two targets are potentially important for megakaryocyte differentiation, since E2F1 was shown to impair megakaryocyte differentiation 25 and MAPK1 was shown to be required for megakaryocyte differentiation
26
.
Effects of miR-28 expression on megakaryocyte proplatelet formation
To assess the functional consequences of miR-28 expression on megakaryocyte proplatelet formation, CD34+ hematopoietic progenitors were infected with bicistronic retroviruses coexpressing miR-28 and GFP, or empty vector and GFP, and then maintained in medium containing Tpo, as described 22 . Megakaryocytes were examined after 14 days of culture. The number of proplatelet-bearing CD41/GFP positive megakaryocytes was significantly inhibited (>50%) by miR-28 expression (Figs. 2E and F). Although we did not co-express JAK2
V617F and miR-28 in these experiments to determine the effect of miR-28 in megakaryocytes expressing JAK2 V617F, our data suggest that miR-28 exerts a negative role on megakaryocyte differentiation. It remains to be determined whether this effect is linked directly to the down-modulation of MPL or to the other targets we identified, such as E2F6 or MAPK1.
Constitutive STAT5 activation in transformed hematopoietic cells is associated with miR-28 expression
We found that the HEL cell line, which has been derived from a patient that relapsed with erythroleukemia after being treated for Hodgkin's lymphoma 14 , and the UKE-1 cell line derived from a patient with ET, that transformed to acute leukemia 27 expressed high levels of miR-28 (Fig. 3A) ; UKE-1 cells are homozygous for the JAK2 V617F mutation 6 , while HEL cells have 8 copies of the JAK2 locus and are homozygous for JAK2 V617F 28 (Fig. 3A) .
Both HEL and UKE-1 cells express much higher levels of miR-28 than UT-7 cells (Fig. 3A) , which is a human megakaryocyte leukemia cell line that expresses very high levels of wild type JAK2.
To test whether miR-28 expression was indeed linked to JAK2 V617F expression, we infected the parental UT-7 cell line, negative for JAK2 V617F and miR-28 expression, with bicistronic retroviral vectors expressing either JAK2 WT or JAK2 V617F together with GFP.
After sorting for equivalent GFP levels, JAK2 V617F mRNA represented only about 12% (11.88 ± 0.42) of the total JAK2 mRNA cell content. A similar increase (about 12%) in the level of JAK2 WT mRNA was observed in UT-7 cells engineered to overexpress JAK2 WT (UT-7 JAK2 WT) ( Supplementary Fig. 4 ). This limited overexpression of JAK2 V617F or JAK2 WT that we could attain is likely due to the fact that UT-7 cells express very high endogenous JAK2 levels (i.e. 5 fold higher than in UKE-1 cells). Nevertheless, miR-28 was expressed at 3-fold higher levels in JAK2 V617F UT-7 cell line, when compared to the JAK2 WT cell line (Fig. 3B ). These data indicate that expression of the constitutive active JAK2
V617F leads to expression of miR-28. Ba/F3 TpoR JAK2WT cell lines did not respond by miR-28 induction after cytokine stimulation. In contrast, the Ba/F3 EpoR JAK2 V617F and Ba/F3 TpoR JAK2 V617F cell lines, expressed 6 and 8 fold more miR-28, and these levels were significantly increased in a dose-dependent manner (not shown) by further cytokine stimulation (Fig. 3C) . Thus, miR-28 is specifically induced by the constitutive JAK2 V617F signaling.
The Ba/F3 cells co-expressing TpoR and JAK2 V617F were then selected for autonomous growth. As expected, miR-28 level further increased when the JAK2 V617F constitutive activity was enhanced (by 4-fold, not shown). The JAK2 inhibitors: AG490, JAK Inhibitor I, AZD1480 and TG101209 were all potent to reduce miR-28 expression (Fig. 4A) , suggesting that miR-28 expression is dependent on the catalytic activity of JAK2 V617F.
Similarly, when Ba/F3 were transformed to autonomous growth by expression of TpoR W515A/L/K or TpoR ∆ 5 (TpoR deleted in the juxtamembrane RWQFP motif that includes W515), which are constitutively active mutants of MPL 10 , we observed an increase in miR-28 expression (Fig. 4B) .
Another means to induce cytokine-independent growth of Ba/F3 cells via constitutive STAT5
activation is to express the Bcr-Abl oncogene; indeed Bcr-Abl also increased miR-28 levels.
Since JAK2 V617F, TpoR W515 mutants and Bcr-Abl are all activating STAT5, we then . The physiologic function of LPP is unknown. Since miR-28 is expressed at 35-fold higher levels in HEL than in UT-7 cells (Fig. 5A) , we tested whether the LPP gene was expressed at higher levels in HEL versus UT-7 cells, in the scenario that miR-28 expression is induced via expression of its host gene, and not driven by an internal promoter.
Indeed, LPP levels are dramatically increased in HEL, when compared to UT-7 cells (Fig.   5A ). In order to localize the promoter of the LPP gene and therefore of miR-28 in HEL cells, (Fig. 5D) .
UT-7 JAK2 V617F and UT-7 JAK2 WT cells was below significance, although the former expressed higher miR-28 levels. This might be due to long miR half-life and the very low levels of JAK2 V617F that could be transduced in UT7 cells. In order to seek for transcriptional activity, RNA pol II ChIP were performed on both promoter sites. We detected an increased RNA pol II binding to promoter A site in JAK2 V617F expressing cell lines compared to JAK2 WT expressing cell lines (Fig. 5D) , suggesting that STAT5 activates the transcription of Prom A site.
Expression of miR-28 in platelets from MPN patients
In order to evaluate whether increased miR-28 expression might be detected in MPN patients, small-size RNA was isolated from platelets of 18 healthy donors and 53 MPNs patients (8 PV, 29 ET and 16 PMF) were extracted and monitored for miR-28 expression levels by StemLoop qRT-PCR ( Figure 6 ). miR-28 was expressed in three out of six JAK2 V617F-positive PV patients, one out of 9 JAK2 V617F-positive ET, 9 out of 20 JAK2 WT ET, one out of six PMF JAK2 WT, and two out of four MPL W515 mutant-positive PMF (Fig. 6A) ; the MPL W515 mutations also lead to constitutive JAK/STAT activation [8] [9] [10] . Taken together, miR-28 is expressed in platelets of about 30% of MPN patients. When we evaluated miR-151 expression in patients' platelets, only two patients, namely ET JAK2 V617F patient-4 and PMF MPL W515L patient-2 displayed significant upregulated levels. We were not able to evaluate miR-708 levels in patients' platelets due to cross-reactivity of the tested probes.
The mean miR-28 platelet level in MPNs was 11 fold greater than in controls (p=0.0137) (Fig. 6B) . In order to evaluate whether a relationship can be established between expression of JAK2 V617F and of miR-28 in platelets, we set-up a genotyping test for the quantitation of JAK2 V617F and JAK2 WT at the mRNA/cDNA level (as platelets do not have genomic Fig. 4 ).
Importantly, the JAK2 V617F levels (ratio to total V617F+WT JAK2) at the mRNA level were similar in granulocytes and platelets from the same patient ( Supplementary Fig. 4 ). This test allowed us to measure levels of JAK2 V617F mRNA in platelets from MPN patients.
miR-28 levels were compared between two platelet groups, one expressing <50% and the other >50% JAK2 V617F. The >50% JAK2 V617F group displayed a 34-fold increase (p=0.0034) in miR-28 expression level, indicating a possible correlation between JAK2
V617F allele burden and miR-28 expression. Importantly, miR-28 is expressed in platelets, but not in granulocytes (Fig. 6C ). Since megakaryocytes are major players in the pathogenicity of MPNs 33,34 , we suggest that these data might be relevant for further understanding of molecular anomalies of this lineage in MPNs.
Separately from the analysis of JAK2 V617F-positive patients, we could observe that 9 out of 20 ET JAK2 WT patients overexpressed miR-28 ( Figure 6A ). Since the ET JAK2 WT group is known to have higher platelet counts 35 , it is possible that miR-28 represents a marker of megakaryocyte proliferation. In order to establish this correlation, a larger study is necessary.
Next we examined the MPL protein levels for 21 (5 PV, 12 ET, 4 PMF) of the 53 MPN patients and asked whether a correlation could be found between high miR-28 levels and MPL down-modulation (Supplementary Figure 3) . Of the five PV patients examined, five had down-modulation of MPL, but only four had high miR-28; PV patient 6 had an allele burden of JAK2 V617F of 93%, down-modulation of MPL and low miR-28 (see Discussion). All four MPL W515L/K PMF patients exhibited strong down-modulation of MPL; two of the For personal use only. on April 13, 2017. by guest www.bloodjournal.org From patients had high miR-28 levels, and a third (PMF MPL W515L patient 2) had overexpressed miR-151 levels. Hereby we therefore report that MPL W515 mutation also is associated with MPL down-modulation.
For ET patients, seven out of twelve did not present platelet MPL protein down-modulation (Supplementary Figure 3) . Two ET patients were positive for JAK2 V617F, ET patients 8 and 7, with allele burdens of 26% and 35%, respectively. No miR-28 or MPL down-modulation could be detected. However, in ET patients normal and mutated clones co-exist, and the levels of miR-28 and MPL that we can detect represent averages of normal and mutated clones. For ET patients that did not exhibit JAK2 V617F, it is impossible to know the allele burden of the putative "other mutations"; interestingly three such ET patients had high miR-28 and no MPL down-modulation. Whether this simply reflects the inability of miR-28 to down-modulate platelet MPL in ET or the presence of a mix of normal and high miR-28/ weak MPL downmodulation is not known. The nature of the other events responsible for JAK2 V617F/ negative ET might also affect the induction and effects of miR-28. The existence of microRNAs in platelets has recently been documented 42 . No miR-28 upregulation was detected in MPN platelets in a microRNA profiling study 43 , since the microarray did not contain any miR-28 probe. Another microRNA-profiling study of PMF granulocytes did not detect miR-28 increases 44 . In agreement with this result, we show that miR-28 is specifically expressed in platelets, but not in granulocytes from the same patient.
Currently, we attempt to identify the precise stage during the megakaryocytic differentiation where miR-28 induction occurs, given that, normally, miR-28 should not be expressed past the pre-megakaryocyte stage 45 .
In conclusion, we found that miR-28 is a potent inhibitor of MPL translation and of several other proteins potentially important for megakaryocyte differentiation, such as E2F6 and ERK2. We suggest that expression of miR-28 might play important roles in the pathogenicity of MPNs, either as part of negative feedbacks of myeloproliferation or as regulator of disease phenotype.
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